Dear All, I’ve written in the past about the creative work done by the Milken Institute on health care financing (26 Mar 2022 newsletter, “Pull mechanisms: Private capital can multiply Subscription (Netflix) and TEV models!”). Milken recently held a 3-day symposium entitled “The Future of Health Summit” (4-6 Nov 2025) during which there was an

Dear All, I wrote in the 4 Oct 2025 newsletter about WHO’s updated reviews of antibacterial therapeutics and diagnostics. Team WHO have now released dashboard versions of the reports: Preclinical pipeline dashboard Clinical pipeline dashboard Underlying .xlsx dataset And for reference, don’t forget that you can find a comparative summary of the priority pathogen lists on this

Dear All, When I wrote earlier this year (23 Jan 2025 newsletter) that the January 2025 PACCARB meeting (Presidential Advisory Council on Combatting Antimicrobial Resistant Bacteria) had been cancelled, we had all hoped this would be a transient adjustment and that the very important work of PACCARB would resume in due course.  Unfortunately, this has

Dear All, I wrote previously (23 Sep 2025 newsletter, “EU’s €253 million, 10-year One Health AMR (OHAMR) Initiative”) about OHAMR (European Partnership on One Health AMR ), the 10-year AMR funding initiative that is the successor to the JPIAMR program. OHAMR have now announced that they will be opening a call on 18 Nov 2025 with

Dear All (and with thanks to Frédéric Peyrane for leading on this newsletter): You will know that we eagerly watching the work in the EU on implementing a set of pull incentives based on use of  ‘transferable data exclusivity voucher’ (TEV), also referred to as a  ‘transferable exclusivity extension voucher’ (TEEV). In brief, the concept is that a TEEV

Dear All, Earlier this year (20 Apr 2025 newsletter), Vivli announced their 2025 AMR Surveillance Data Challenge. Funded by Johnson & Johnson, Paratek, Pfizer and a National Institutes of Health (NIH) award1 the goal of this challenge is to produce new insights using existing industry AMR surveillance data. This is the third challenge issued by Vivli,

Dear All, WHO have just (2 Oct 2025) released a pair of reports on therapeutics and diagnostics for bacterial pathogens, with a focus on how these advance our tools for priority bacterial pathogens. Here are the links you need: WHO 2025 update on the preclinical and clinical antibacterial pipeline Title: “Analysis of antibacterial agents in

Dear All, PACE (Pathways to Antimicrobial Clinical Efficacy), a large UK-based public-private funder, have announced a £6 million funding round for projects in the hit-to-lead and lead optimization stages. The call is for antibacterial projects that target WHO priority Gram-negative pathogens (Enterobacteriaceae, A. baumannii and P. aeruginosa; see the AMR.Solutions summary of the priority pathogen

Dear All, The EU have today announced the European Partnership on One Health AMR (OHAMR), a major AMR funding initiative that will run for 10 years (press release, webpage)! As a bit of background, the EU have invested more than EUR 1 billion in hundreds of AMR-focused projects over the past ~15 years. From my